Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study
Clinical Hematology International · 02.11.2026 · 8 (4)
DOI: 10.46989/001c.172867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International, online erschienen am 02.11.2026. Verfasst von Kurumi Kondo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary central nervous system lymphoma (PCNSL) is an aggressive disease with heterogeneous clinical outcomes, and readily measurable prognostic biomarkers remain limited. We retrospectively analyzed 21 patients with newly diagnosed PCNSL who received high-dose methotrexate-based therapy at a single institution between 2006 and 2023. The median age was 68 years, and 12 patients had deep-structure involvement. Median overall survival (OS) and progression-free survival were 41 and 31 months, respectively. In univariate analyses, pretreatment serum soluble interleukin-2 receptor (sIL-2R) level (p = 0.0185), cerebrospinal fluid protein level (p = 0.0401), and receipt of radiotherapy (p = 0.0377) were significantly associated with OS. Receiver operating characteristic analysis of pretreatment serum sIL-2R for 3-year OS yielded an area under the curve of 0.869; a candidate threshold of 566 U/mL showed a sensitivity of 85.7% and specificity of 83.3%. Pretreatment serum sIL-2R was associated with OS in this small retrospective cohort, and this exploratory finding warrants validation in larger independent studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
ORCID-Profile: Masayuki Kobayashi
Zitieren
APA
Kondo, K., Kawamata, T., Kosugi, N., & Kobayashi, M. (2026). Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study. Clinical Hematology International, 8(4). https://doi.org/10.46989/001c.172867
Vancouver
Kondo K, Kawamata T, Kosugi N, Kobayashi M. Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study. Clinical Hematology International. 2026;8(4). doi:10.46989/001c.172867
BibTeX
@article{Kondo2026,
author = {Kondo, Kurumi and Kawamata, Toyotaka and Kosugi, Nobuharu and Kobayashi, Masayuki},
title = {Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study},
journal = {Clinical Hematology International},
year = {2026},
volume = {8},
number = {4},
doi = {10.46989/001c.172867}
}
EUVIMED